Application of human EIF3A gene and related drugs

A gene and drug technology, applied in the field of the use of human EIF3A gene and related drugs, can solve the problem of few reports on EIF3A

Pending Publication Date: 2016-07-20
FOURTH MILITARY MEDICAL UNIVERSITY
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] There are few report...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of human EIF3A gene and related drugs
  • Application of human EIF3A gene and related drugs
  • Application of human EIF3A gene and related drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0084] Example 1 Preparation of RNAi lentivirus against human EIF3A gene

[0085] 1. Screening for effective siRNA targets against the human EIF3A gene

[0086] Retrieve EIF3A (NM_00375) gene information from Genbank; design effective siRNA targets for EIF3A gene. Table 1 lists one of the effective siRNA target sequences for the EIF3A gene.

[0087] Table 1 is targeted at the siRNA target sequence of human EIF3A gene

[0088]

[0089] 2. Preparation of lentiviral vector

[0090] Aiming at the siRNA target (taking SEQIDNO: 1 as an example) synthetic double-stranded DNA Oligo sequence (table 2) containing AgeI and EcoRI restriction endonuclease at both ends; Acting on the pGCSIL-GFP vector ( Provided by Shanghai Jikai Gene Chemical Technology Co., Ltd., figure 1 ), to linearize it, and identify the digested fragments by agarose gel electrophoresis.

[0091] Table 2 Double-stranded DNA Oligo with sticky ends containing AgeI and EcoRI restriction sites at both ends

[009...

Embodiment 2

[0110] Example 2 EIF3A expression abundance detection in 5 strains of colon cancer cells

[0111] Five colon cancer cell lines HCT116, RKO, SW480, SW620, and LOVO in the logarithmic growth phase were digested with trypsin to make cell suspension (the number of cells was about 5×10 4 / ml) were inoculated in a 6-well plate and cultured until the cell confluency reached about 30%. According to the multiplicity of infection (MOI, RKO: 10) value, an appropriate amount of the virus prepared in Example 1 was added, the culture medium was replaced after 24 hours of cultivation, and the cells were collected after the infection time reached 4 days. Total RNA was extracted according to the instruction manual of Invitrogen's Trizol. The specific method is:

[0112] 1) Collect the cells, centrifuge at 1000rpm for 5min, remove the supernatant, add 1ml Trizol to the cell pellet, pipette quickly and let stand at room temperature for 5min, then transfer to a new 1.5mleppendorf tube;

[0113...

Embodiment 3

[0129] Example 3 Real-time fluorescent quantitative RT-PCR method to detect the silencing efficiency of EIF3A gene

[0130] Colon cancer RKO cells in the logarithmic growth phase were digested with trypsin to make a cell suspension (the number of cells was about 5×10 4 / ml) were inoculated in a 6-well plate and cultured until the cell confluency reached about 30%. According to the multiplicity of infection (MOI, RKO: 10) value, an appropriate amount of the virus prepared in Example 1 was added, the culture medium was replaced after 24 hours of cultivation, and the cells were collected after the infection time reached 4 days. Total RNA was extracted according to the instruction manual of Invitrogen's Trizol. Then, according to the M-MLV instruction manual of Promega Company, the RNA was reverse-transcribed to obtain cDNA (see Table 7 for the reverse transcription reaction system, react at 42°C for 1 hour, and then bathe in a water bath at 70°C for 10 minutes to inactivate the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of human EIF3A gene and related drugs. The invention discloses an application of the human EIF3A gene in tumor therapy, tumor diagnosis and drug preparation. The invention also further constructs human EIF3A gene small interfering RNA, human EIF3A gene interfering nucleic acid construct and human EIF3A gene interfering lentivirus and discloses their applications. The siRNA or the nucleic acid construct and lentivirus containing the siRNA sequence can specifically inhibit expression of the human EIF3A gene, especially lentivirus can efficiently infect target cell and efficiently inhibit expression of the EIF3A gene in the target cell so as to further inhibit growth of tumor cells and promote tumor cell apoptosis. Thus, the invention is of great significance in tumor therapy.

Description

technical field [0001] The invention relates to the field of biotechnology, and more specifically relates to the use of human EIF3A gene and related medicines. Background technique [0002] RNA interference (RNAi) is short double-stranded RNA (dsRNA) composed of nucleotides for post-transcriptional gene silencing. It can efficiently and specifically block the expression of a specific gene in the body, leading to its degradation, thereby causing the silencing of a specific gene in the organism, and causing the cells to show the absence of a certain gene phenotype. It is a commonly used research gene emerging in recent years. Functional, laboratory techniques for finding cures for disease. Studies have shown that double-stranded RNA with a length of 21-23nt can specifically cause RNAi at the transcriptional and post-transcriptional levels (TuschlT, ZamorePD, SharpPA, BartelDP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21to23nucleotide intervals. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/68C12N15/113C12N15/867A61K31/713A61P35/00
Inventor 聂勇战吴开春董加强胡思隽窦建华唐光波吴健
Owner FOURTH MILITARY MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products